| These findings indicated that the lncRNA ZFAS1 may be a tumor suppressor in breast cancer, and thus, may serve as a potential therapeutic target for patients with breast cancer. | breast, |
| Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma. | liver, |
| Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. | colorectal, |
| ZFAS1 over-expression confers an oncogenic function in gastric cancer and this function is partly dependent on repressing KLF2 and NKD2 | gastric, |
| ZFAS1 may function as an oncogene by modulating ZEB1 to induce EMT. Manipulation of ZFAS1 level may be a novel approach to suppress colonic cancer progression. | colorectal, |
| ZFAS1 could exhibit a tumor oncogenic role in glioma progression. | glioma, |
| The study suggested that ZFAS1 could act as an oncogene in colorectal cancer tumorigenesis, and discovered the functional regulatory pathway of ZFAS1 sponging miR-484. | colorectal, |
| ZFAS1 could serve as an oncogene in the tumorigenesis of bladder cancer, and discovered the functional regulatory network of ZFAS1 sponging miR-329. | bladder, |
| ata suggest that long non-coding RNA ZFAS1 may function as oncogene via destabilization of tumor suppressor protein p53 (p53) and through cyclin-dependent kinase 1 (CDK1)/cyclin B1 complex leading to cell cycle progression and inhibition of apoptosis. | None |
| ZFAS1 has been shown to have oncogenic function in tumourigenesis and tumour progression and may act as a potential cancer- specific molecular biomarker in the general diagnosis, prognosis, and treatment of cancer. | None |
| ZFAS1 displays oncogenic properties, regulates important processes associated with EMT, cancer-initiating cells, and metastases, and might affect patients_ clinical outcomes. ZFAS1 likely regulates the cell phenotype through miR-150-5p and its downstream targets. | None |